RT Journal Article
SR Electronic
A1 Misra-Press, Anita
T1 Age-Stratified Subgroup Analysis of SQUIRE in Patients With Stage IV Squamous NSCLC
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 8
SP 14
OP 14
DO 10.1177/1559897715588298
UL http://mdc.sagepub.com/content/15/8/14.1.abstract
AB An age-stratified subgroup analysis of the SQUIRE trial demonstrated that patients aged < 70 years exhibited significant survival benefits when necitumumab was added to gemcitabine/cisplatin chemotherapy as first-line treatment for stage IV squamous non–small cell lung cancer. This survival advantage was not observed in the elderly ≥ 70-year subgroup.